Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates
Yuan Chen, Divya Samineni, Sophie Mukadam et al. · Clinical Pharmacokinetics · 2014
Cited by 49 works. doi:10.1007/s40262-014-0182-x
Authors
- Yuan Chen
- Divya Samineni
- Sophie Mukadam
- Harvey Wong
- Ben‐Quan Shen
- Dan Lu
- Sandhya Girish
- Cornelis E. C. A. Hop
- Jin Y. Jin
- Chunze Li
References
- Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
- Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
- Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
- Prediction of Pharmacokinetics Prior to In Vivo Studies. 1. Mechanism‐Based Prediction of Volume of Distribution
- Bioanalytical Assay Strategies for The Development of Antibody–Drug Conjugate Biotherapeutics
- Bioanalysis of Antibody–Drug Conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group Position Paper
- Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review
- CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies
- Pharmacokinetic Considerations for Antibody Drug Conjugates
- Applications of minimal physiologically-based pharmacokinetic models